A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety,
tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid
leukemia (AML). Ribavirin BID may be added to brequinar twice weekly in eligible subjects.